GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2021-2028
The global Alzheimer’s disease therapeutics and diagnostics market is projected to register a CAGR of 5.40% between 2021 and 2028, and is anticipated to generate revenue of $9979.0 million by 2028. Alzheimer’s disease is a degenerative, progressive ailment that attacks the brain’s nerve cells, resulting in memory loss, behavioral changes as well as changes in thinking and language skills. During the COVID-19 outbreak, some of the clinical trials for Alzheimer’s disease were postponed due to the fear of infections.
GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET FORECAST 2021-2028
Global Alzheimer’s Disease Therapeutics and Diagnostics Market by Therapeutics and Diagnostics (Therapeutics (Therapeutics by Drugs (Marketed Drugs, Pipeline Drugs), Therapeutics by Disease Stage (Late Stage: Severe Ad, Early/middle Stage: Mild to Moderate Ad, Prodromal Stage), Therapeutics by Generic and Branded (Branded, Generic)), Diagnostics (Lumbar Puncture Test, Positron Emission Tomography, Electroencephalography, Magnetic Resonance Imaging, Computed Tomography, Other Diagnostics)) and by Geography.
The global Alzheimer’s disease therapeutics and diagnostics market is projected to register a CAGR of 5.40% between 2021 and 2028, and is anticipated to generate revenue of $9979.0 million by 2028.
Alzheimer’s disease is a degenerative, progressive ailment that attacks the brain’s nerve cells, resulting in memory loss, behavioral changes as well as changes in thinking and language skills. During the COVID-19 outbreak, some of the clinical trials for Alzheimer’s disease were postponed due to the fear of infections. A proportion of people with dementia are in care homes. They tend to be older, and have multiple other health conditions.
To know more about this report, request a free sample report.
Key factors propelling the global Alzheimer’s disease therapeutics and diagnostics market growth is:
- Growing geriatric population
- Alzheimer’s disease is the key reason for dementia among the old age population.
- According to World Population Prospects 2019 (United Nations, 2019), by 2050, 1 in 6 people in the world will be over the age of 65, up from 1 in 11 in 2019.
- Rise in the pervasiveness of Alzheimer’s disease
- Emerging novel diagnostic technologies
- Increasing pipeline drugs
Major growth restraining factors:
- Failure of the late-stage drugs
- Stringent government regulations
- Stringent regulations for drug development and commercialization are restraining market growth.
- For instance, as per the U.S. Food and Drug Administration (FDA), a company that intends to manufacture a new drug prior to conducting clinical trials in the US has to submit an Investigational New Drug application (IND) for conducting clinical trials that are approved by the FDA based on the result of animal pharmacology and toxicology studies.
- Lack of the availability of surrogate markers
The report scope of the global Alzheimer’s disease therapeutics and diagnostics market includes the segmentation analysis of therapeutics and diagnostics. One of these segments is further classified to provide a detailed analysis of the studied market.
Market by Therapeutics and Diagnostics:
- Therapeutics
- The therapeutics segment is set to be prominent with regard to CAGR and revenue share by 2028.
- The therapeutics market is segmented into drugs, disease stage & generic, and branded. The market drugs comprise NMDA receptor antagonists, Cholinesterase inhibitors, and others. Cholinesterase inhibitors are medications that avert the breakdown of acetylcholine in the body. In people with advanced Alzheimer’s disease, certain nerve cells are much less active.
- The general course of AD is categorized into seven stages according to disease severity. Since it is difficult to clearly distinguish each step, in drug development, a three-stage categorization is preferred, mild, moderate, and severe AD.
- Diagnostics
Geographically, the global Alzheimer’s disease therapeutics and diagnostics market has been segmented based on four major regions, which includes:
- North America: The United States and Canada
- North America is evaluated to dominate the global market by 2028.
- According to the National Institutes of Health (NIH), an estimated 5.8 million Americans are living with Alzheimer’s disease in 2020.
- Further, as per the Alzheimer Society of Canada, about 25,000 new cases of dementia are being diagnosed every year. By 2031, this is expected to rise to 937,000, an increase of 66%, as nearly 25,000 new cases of dementia are diagnosed every year.
- Europe: The United Kingdom, Germany, Italy, France, Belgium, Russia, Poland, and Rest of Europe
- Asia Pacific: India, Australia & New Zealand, China, South Korea, Japan, Thailand, Indonesia, Vietnam, and Rest of Asia Pacific
- Rest of World: Latin America, the Middle East & Africa
The major market players in the global Alzheimer’s disease therapeutics and diagnostics market are:
- Hoffmann-la Roche
- Johnson & Johnson
- Merck & Co Inc
- Novartis AG
- Pfizer Inc
- Others
Key strategies adopted by some of the Alzheimer’s disease therapeutics and diagnostics companies:
In November, 2020, Johnson & Johnson announced the expansion to the partnership between its Janssen Pharmaceutical Corporations and the Biomedical Advanced Research and Development Authority. Also, in November 2020, GenesisCare and GE Healthcare announced a strategic partnership to advance the patient outcomes for cancer and heart disease.
Key findings of the global Alzheimer’s disease therapeutics and diagnostics market:
- There is rising R&D investment in the biomarkers for early detection of dementia.
- Computed tomography is used in the diagnostics of Alzheimer’s disease.
- There have been advancements in in-vitro diagnostic techniques.
- There is an increasing demand for personalized medicines.
Frequently Asked Questions & Answers (FAQs):
- What are the growth prospects of the Alzheimer’s disease therapeutics and diagnostics market?
A: There are millions of people worldwide with a form of dementia. The most common is Alzheimer’s disease. According to the World Health Organization report, almost 50 million people around the world live with dementia, and is likely to increase in the future, thereby making it a major market for investment purposes.
- What type of drug therapies could slow or stop the progress of the disease?
A: Some of the promising targets for next-generation drug therapies under investigation in current research studies include Tau protein, Beta-secretase (BACE), Inflammation, and 5-HT2A receptor. These drugs are anticipated to interrupt the disease process by impacting one or more of the brain changes associated with Alzheimer’s, which offers potential targets to slow or stop the progress of the disease.
- What is the role of biomarkers in the treatment of Alzheimer’s disease?
A: Biomarkers are a promising tool for the diagnosis of Alzheimer’s disease, and the last two decades have experienced an enormous expansion in research on fluid biomarkers for AD. Currently, the core AD biomarkers such as CSF biomarkers T-tau, P-tau, are a part of the research diagnostic criteria.
- RESEARCH SCOPE & METHODOLOGY
- STUDY OBJECTIVES
- SCOPE OF STUDY
- METHODOLOGY
- ASSUMPTIONS & LIMITATIONS
- EXECUTIVE SUMMARY
- MARKET SIZE & ESTIMATES
- MARKET OVERVIEW
- MARKET DYNAMICS
- PARENT MARKET ANALYSIS
- KEY DRIVERS
- GROWING GERIATRIC POPULATION
- RISE IN THE PERVASIVENESS OF ALZHEIMER’S DISEASE
- EMERGING NOVEL DIAGNOSTIC TECHNOLOGIES
- INCREASING PIPELINE DRUGS
- KEY RESTRAINTS
- FAILURE OF THE LATE-STAGE DRUGS
- STRINGENT GOVERNMENT REGULATIONS
- LACK OF THE AVAILABILITY OF SURROGATE MARKERS
- KEY ANALYTICS
- PORTER’S FIVE FORCE ANALYSIS
- THREAT OF NEW ENTRY
- THREAT OF SUBSTITUTION
- BUYER’S POWER
- SUPPLIER’S POWER
- COMPETITIVE RIVALRY
- IMPACT OF COVID-19 ON ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
- KEY BUYING CRITERIA
- ETYMOLOGY OF ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
- SUPPLY CHAIN ANALYSIS
- PHASES AND STERNNESS OF ALZHEIMER’S DISEASE
- OPPORTUNITY MATRIX
- VENDOR LANDSCAPE
- KEY INVESTMENT INSIGHTS
- PORTER’S FIVE FORCE ANALYSIS
- MARKET BY THERAPEUTICS AND DIAGNOSTICS
- THERAPEUTICS
- THERAPEUTICS BY DRUGS
- MARKETED DRUGS
- PIPELINE DRUGS
- THERAPEUTICS BY DISEASE STAGE
- LATE STAGE: SEVERE AD
- EARLY/MIDDLE STAGE: MILD TO MODERATE AD
- PRODROMAL STAGE
- THERAPEUTICS BY GENERIC AND BRANDED
- BRANDED
- GENERIC
- THERAPEUTICS BY DRUGS
- DIAGNOSTICS
- LUMBAR PUNCTURE TEST
- POSITRON EMISSION TOMOGRAPHY
- ELECTROENCEPHALOGRAPHY
- MAGNETIC RESONANCE IMAGING
- COMPUTED TOMOGRAPHY
- OTHER DIAGNOSTICS
- THERAPEUTICS
- GEOGRAPHICAL ANALYSIS
- NORTH AMERICA
- MARKET SIZE & ESTIMATES
- KEY GROWTH ENABLERS
- KEY CHALLENGES
- KEY PLAYERS
- COUNTRY ANALYSIS
- THE UNITED STATES
- CANADA
- EUROPE
- MARKET SIZE & ESTIMATES
- KEY GROWTH ENABLERS
- KEY CHALLENGES
- KEY PLAYERS
- COUNTRY ANALYSIS
- GERMANY
- FRANCE
- UNITED KINGDOM
- ITALY
- RUSSIA
- BELGIUM
- POLAND
- REST OF EUROPE
- ASIA PACIFIC
- MARKET SIZE & ESTIMATES
- KEY GROWTH ENABLERS
- KEY CHALLENGES
- KEY PLAYERS
- COUNTRY ANALYSIS
- CHINA
- JAPAN
- INDIA
- AUSTRALIA & NEW ZEALAND
- SOUTH KOREA
- THAILAND
- INDONESIA
- VIETNAM
- REST OF ASIA PACIFIC
- REST OF WORLD
- MARKET SIZE & ESTIMATES
- KEY GROWTH ENABLERS
- KEY CHALLENGES
- KEY PLAYERS
- REGIONAL ANALYSIS
- LATIN AMERICA
- MIDDLE EAST & AFRICA
- NORTH AMERICA
- COMPETITIVE LANDSCAPE
- KEY STRATEGIC DEVELOPMENTS
- MERGER & ACQUISITIONS
- PRODUCT LAUNCH & DEVELOPMENTS
- PARTNERSHIP, CONTRACT/AGREEMENT & COLLABORATION
- BUSINESS EXPANSION/ APPROVAL/ ANNOUNCEMENT
- COMPANY PROFILES
- ALLERGAN PLC (ACQUIRED BY ABBVIE)
- AMARANTUS BIOSCIENCE HOLDINGS INC
- BAXTER INTERNATIONAL INC.
- BIOGEN INC
- COGNOPTIX INC
- EISAI CO. LTD
- ELI LILLY & COMPANY
- HOFFMANN-LA ROCHE
- GE HEALTHCARE
- JOHNSON & JOHNSON
- LUPIN LIMITED
- MERCK & CO INC
- NOVARTIS AG
- PFIZER INC
- SUN PHARMACEUTICALS INDUSTRIES LTD
- KEY STRATEGIC DEVELOPMENTS
TABLE LIST
TABLE 1: MARKET SNAPSHOT – ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS
TABLE 2: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 3: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 4: GLOBAL THERAPEUTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 5: GLOBAL THERAPEUTICS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 6: GLOBAL THERAPEUTICS MARKET, BY DRUGS, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 7: GLOBAL THERAPEUTICS MARKET, BY DRUGS, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 8: GLOBAL MARKETED DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 9: GLOBAL MARKETED DRUGS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 10: GLOBAL PIPELINE DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 11: GLOBAL PIPELINE DRUGS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 12: GLOBAL THERAPEUTICS MARKET, BY DISEASE STAGE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 13: GLOBAL THERAPEUTICS MARKET, BY DISEASE STAGE, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 14: GLOBAL LATE STAGE: SEVERE AD MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 15: GLOBAL LATE STAGE: SEVERE AD MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 16: GLOBAL EARLY/MIDDLE STAGE: MILD TO MODERATE AD MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 17: GLOBAL EARLY/MIDDLE STAGE: MILD TO MODERATE AD MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 18: GLOBAL PRODROMAL STAGE MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 19: GLOBAL PRODROMAL STAGE MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 20: GLOBAL THERAPEUTICS MARKET, BY GENERIC AND BRANDED, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 21: GLOBAL THERAPEUTICS MARKET, BY GENERIC AND BRANDED, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 22: GLOBAL BRANDED MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 23: GLOBAL BRANDED MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 24: GLOBAL GENERIC MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 25: GLOBAL GENERIC MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 26: GLOBAL DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 27: GLOBAL DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 28: GLOBAL DIAGNOSTICS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 29: GLOBAL DIAGNOSTICS MARKET, BY TYPE, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 30: GLOBAL LUMBAR PUNCTURE TEST MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 31: GLOBAL LUMBAR PUNCTURE TEST MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 32: GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 33: GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 34: GLOBAL ELECTROENCEPHALOGRAPHY MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 35: GLOBAL ELECTROENCEPHALOGRAPHY MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 36: GLOBAL MAGNETIC RESONANCE IMAGING MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 37: GLOBAL MAGNETIC RESONANCE IMAGING MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 38: GLOBAL COMPUTED TOMOGRAPHY MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 39: GLOBAL COMPUTED TOMOGRAPHY MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 40: GLOBAL OTHER DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 41: GLOBAL OTHER DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 42: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 43: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 44: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 45: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 46: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 47: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 48: ASIA PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 49: ASIA PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2021-2028 (IN $ MILLION)
TABLE 50: REST OF WORLD ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2020 (IN $ MILLION)
TABLE 51: REST OF WORLD ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2021-2028 (IN $ MILLION)
FIGURE LIST
FIGURE 1: PIPELINE DRUGS RELATED TO ALZHEIMER’S DISEASE
FIGURE 2: PORTER’S FIVE FORCE ANALYSIS
FIGURE 3: SUPPLY CHAIN ANALYSIS
FIGURE 4: OPPORTUNITY MATRIX
FIGURE 5: VENDOR LANDSCAPE
FIGURE 6: KEY INVESTMENT INSIGHTS
FIGURE 7: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2021-2028 ($ MILLION)
FIGURE 8: GLOBAL THERAPEUTICS MARKET, BY MARKETED DRUGS, 2021-2028 ($ MILLION)
FIGURE 9: GLOBAL THERAPEUTICS MARKET, BY PIPELINE DRUGS, 2021-2028 ($ MILLION)
FIGURE 10: GLOBAL THERAPEUTICS MARKET, BY LATE STAGE: SEVERE AD, 2021-2028 ($ MILLION)
FIGURE 11: GLOBAL THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD TO MODERATE AD, 2021-2028 ($ MILLION)
FIGURE 12: GLOBAL THERAPEUTICS MARKET, BY PRODROMAL STAGE, 2021-2028 ($ MILLION)
FIGURE 13: GLOBAL THERAPEUTICS MARKET, BY BRANDED, 2021-2028 ($ MILLION)
FIGURE 14: GLOBAL THERAPEUTICS MARKET, BY GENERIC, 2021-2028 ($ MILLION)
FIGURE 15: GLOBAL ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2021-2028 ($ MILLION)
FIGURE 16: GLOBAL DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST, 2021-2028 ($ MILLION)
FIGURE 17: GLOBAL DIAGNOSTICS MARKET, BY POSITRON EMISSION TOMOGRAPHY, 2021-2028 ($ MILLION)
FIGURE 18: GLOBAL DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY, 2021-2028 ($ MILLION)
FIGURE 19: GLOBAL DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE IMAGING, 2021-2028 ($ MILLION)
FIGURE 20: GLOBAL DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY, 2021-2028 ($ MILLION)
FIGURE 21: GLOBAL DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2021-2028 ($ MILLION)
FIGURE 22: NORTH AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
FIGURE 23: THE UNITED STATES ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
FIGURE 24: CANADA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
FIGURE 25: EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
FIGURE 26: UNITED KINGDOM ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
FIGURE 27: FRANCE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
FIGURE 28: GERMANY ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
FIGURE 29: ITALY ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
FIGURE 30: RUSSIA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
FIGURE 31: BELGIUM ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
FIGURE 32: POLAND ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
FIGURE 33: REST OF EUROPE ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
FIGURE 34: ASIA PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2020 & 2028 (IN %)
FIGURE 35: CHINA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
FIGURE 36: INDIA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
FIGURE 37: JAPAN ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
FIGURE 38: AUSTRALIA & NEW ZEALAND ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
FIGURE 39: SOUTH KOREA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
FIGURE 40: THAILAND ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
FIGURE 41: INDONESIA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
FIGURE 42: VIETNAM ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
FIGURE 43: REST OF ASIA PACIFIC ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
FIGURE 44: REST OF WORLD ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2020 & 2028 (IN %)
FIGURE 45: LATIN AMERICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
FIGURE 46: MIDDLE EAST & AFRICA ALZHEIMER’S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2021-2028 (IN $ MILLION)
- MARKET BY THERAPEUTICS AND DIAGNOSTICS
- THERAPEUTICS
- THERAPEUTICS BY DRUGS
- MARKETED DRUGS
- PIPELINE DRUGS
- THERAPEUTICS BY DISEASE STAGE
- LATE STAGE: SEVERE AD
- EARLY/MIDDLE STAGE: MILD TO MODERATE AD
- PRODROMAL STAGE
- THERAPEUTICS BY GENERIC AND BRANDED
- BRANDED
- GENERIC
- THERAPEUTICS BY DRUGS
- DIAGNOSTICS
- LUMBAR PUNCTURE TEST
- POSITRON EMISSION TOMOGRAPHY
- ELECTROENCEPHALOGRAPHY
- MAGNETIC RESONANCE IMAGING
- COMPUTED TOMOGRAPHY
- OTHER DIAGNOSTICS
- THERAPEUTICS
- GEOGRAPHICAL ANALYSIS
- NORTH AMERICA
- THE UNITED STATES
- CANADA
- EUROPE
- UNITED KINGDOM
- FRANCE
- GERMANY
- ITALY
- RUSSIA
- BELGIUM
- POLAND
- REST OF EUROPE
- ASIA PACIFIC
- CHINA
- INDIA
- JAPAN
- AUSTRALIA & NEW ZEALAND
- SOUTH KOREA
- THAILAND
- INDONESIA
- VIETNAM
- REST OF ASIA PACIFIC
- REST OF WORLD
- LATIN AMERICA
- MIDDLE EAST & AFRICA
- NORTH AMERICA
To request a free sample copy of this report, please complete the form below :
We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.